Eli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended for NHS use in England and Wales as a treatment for atopic dermatitis, also known as eczema.
Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a deal ...
Background A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome. Objectives To describe clinical characteristics, laboratory findings ...
⊥ Division of Cell Signaling and Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH. U.K. *Phone: 617-582-8590. Fax: 617-582-8615. E-mail: [email protected] Article Views are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results